Psychemedics Corporation
PMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | -0.01 | -0.44 | 0.71 |
| FCF Yield | 6.41% | -9.63% | 17.04% | 0.60% |
| EV / EBITDA | 67.49 | -69.02 | 11.83 | 10.79 |
| Quality | ||||
| ROIC | -29.20% | -39.35% | -7.34% | -15.36% |
| Gross Margin | 36.07% | 38.07% | 36.81% | 41.21% |
| Cash Conversion Ratio | -0.50 | 0.36 | -4.51 | -0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.95% | -3.91% | 5.72% | -12.89% |
| Free Cash Flow Growth | 151.44% | -134.81% | 1,927.16% | 104.57% |
| Safety | ||||
| Net Debt / EBITDA | -1.31 | -1.33 | -0.53 | 0.80 |
| Interest Coverage | -72.81 | -171.82 | 0.00 | -71.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 7,322,500.00 |
| Cash Conversion Cycle | 33.40 | 41.14 | 48.72 | 74.78 |